List of Excipients in Branded Drug GAVRETO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genentech Inc	GAVRETO	pralsetinib	50242-210	ANHYDROUS CITRIC ACID	2042-07-07
Genentech Inc	GAVRETO	pralsetinib	50242-210	HYDROXYPROPYL CELLULOSE	2042-07-07
Genentech Inc	GAVRETO	pralsetinib	50242-210	MAGNESIUM STEARATE	2042-07-07
Genentech Inc	GAVRETO	pralsetinib	50242-210	SODIUM BICARBONATE	2042-07-07

Gavreto (Pralsetinib) Excipient Strategy and Commercial Opportunities

Last updated: September 13, 2026

Gavreto is the U.S. brand for pralsetinib, an oral RET kinase inhibitor developed by Blueprint Medicines and commercialized with Roche/Genentech. Its commercial opportunity has shifted following the voluntary U.S. withdrawal of Gavreto in 2024. The strongest excipient opportunities are therefore outside a direct U.S. generic launch: regional products, lifecycle reformulation, contract manufacturing, pediatric or administration-friendly presentations, and formulations that improve exposure consistency.

The core formulation is a hard capsule containing pralsetinib, with a relatively conventional solid oral excipient system. The principal technical opportunity is not to reproduce the capsule exactly, but to solve bioavailability, food-effect, dose flexibility, stability, and supply-chain problems without creating new regulatory or patent barriers.

What is Gavreto and what formulation does it use?

Gavreto contains pralsetinib, a selective RET inhibitor. The approved dosage form is an oral hard capsule supplied in a 100 mg strength. The U.S. prescribing information directs administration on an empty stomach, at least two hours after and at least one hour before food, indicating that food and gastrointestinal conditions are important formulation and labeling considerations.[1]

Gavreto formulation profile

Attribute	Publicly reported characteristic
Active ingredient	Pralsetinib
Brand	Gavreto
Therapeutic class	RET kinase inhibitor
Primary dosage form	Immediate-release hard capsule
U.S. strength	100 mg
Original sponsor	Blueprint Medicines
U.S. commercial partner	Genentech/Roche
Initial FDA approval	September 2020
Approval pathway	Accelerated approval
U.S. status	Voluntarily withdrawn in 2024
Administration constraint	Empty-stomach dosing
Main formulation challenge	Exposure control in the presence of food and gastrointestinal variability

The U.S. label identifies inactive ingredients in the capsule formulation, including commonly used solid-dose excipients such as hypromellose, microcrystalline cellulose, magnesium stearate, and sodium lauryl sulfate. The capsule shell contains standard hard-capsule components and colorants.[1] Exact excipient selection can vary by market, manufacturing site, and approved presentation.

The formulation appears designed as an immediate-release powder or blend-filled capsule rather than as a modified-release system. That creates a relatively accessible formulation platform for generic manufacturers, but it also leaves room for differentiated products that reduce food restrictions or improve dose administration.

What excipient functions are important in pralsetinib capsules?

The excipient system has four commercial functions: powder processing, wetting and dissolution, capsule filling, and stability control.

Microcrystalline cellulose

Microcrystalline cellulose is likely used as a diluent and processing aid. It can improve bulk density, flow, blend uniformity, and capsule-fill reproducibility. For a low-dose or moderately potent kinase inhibitor, content uniformity is a central manufacturing issue because the active pharmaceutical ingredient may represent only part of the capsule mass.

A manufacturer evaluating a substitute should assess:

• Blend segregation during transfer and encapsulation
• Particle-size distribution
• Bulk and tapped density
• Moisture sensitivity
• Content uniformity across long production runs
• Compatibility with the API and surfactant system

Spray-dried grades, silicified microcrystalline cellulose, and alternative cellulose-based fillers could reduce flow problems. Each substitution creates a potential formulation-development package and, depending on the claims, a possible formulation patent position.

Sodium lauryl sulfate

Sodium lauryl sulfate is a wetting agent and surfactant. Its presence is commercially relevant because pralsetinib may require assistance with wetting or dissolution. Surfactant selection can affect dissolution rate, precipitation after gastric dilution, and exposure variability.

Potential substitutes include poloxamers, sodium docusate, polysorbates, or self-emulsifying excipient systems. These alternatives may improve dissolution, but they also introduce risks involving:

• Chemical degradation
• Capsule-shell compatibility
• Local gastrointestinal tolerability
• Batch-to-batch impurity control
• Regulatory justification for excipient exposure

A surfactant-reduced formulation could have value where sodium lauryl sulfate is restricted, poorly tolerated, or difficult to source.

Magnesium stearate

Magnesium stearate is generally used as a lubricant. Its level and mixing time are important. Excessive lubrication can reduce wettability and slow dissolution, while insufficient lubrication can cause sticking, poor ejection, and capsule-fill variation.

Potential alternatives include sodium stearyl fumarate, stearic acid, or lower-lubricant processing using improved excipient grades. This area offers a practical manufacturing opportunity, particularly for high-volume contract manufacturing, but claims based only on substituting one lubricant for another may face limited patent strength unless linked to a measurable dissolution or stability advantage.

Hypromellose and capsule-shell materials

Hypromellose may function as an excipient in the fill or as a capsule-shell material, depending on the product configuration. Hypromellose capsules can provide an alternative to gelatin where manufacturers seek vegetarian, religious-compliance, lower-moisture, or improved supply-chain characteristics.

For pralsetinib, capsule-shell selection can affect:

• Moisture transfer into or out of the fill
• Dissolution under biorelevant conditions
• Shell brittleness
• Printing and color uniformity
• Stability in hot and humid markets

A low-moisture capsule shell may have commercial value in tropical markets or in packaging systems with limited desiccant capacity.

What excipient strategies could improve Gavreto or pralsetinib products?

The most valuable strategies target the empty-stomach requirement, formulation robustness, and patient administration.

Food-effect mitigation

The current dosing restriction creates an adherence burden. A formulation that maintains acceptable exposure with food would be commercially differentiated if supported by clinical pharmacokinetic data and a revised label.

Possible approaches include:

1. Amorphous solid dispersions to improve dissolution and reduce dependence on gastric conditions.
2. Lipid-based formulations to stabilize solubilization after food intake.
3. Self-emulsifying drug-delivery systems in softgel or liquid-filled hard capsules.
4. Polymer-surfactant combinations that limit precipitation after dilution.
5. Particle-engineered API, including nanocrystals or spray-dried dispersions.
6. A higher-solubility salt, cocrystal, or solid form, where chemically and legally available.

Food-effect mitigation is the strongest excipient-led opportunity because it addresses a known prescribing limitation rather than providing only a manufacturing substitution.

Reduced-dose or dose-flexible presentation

Pralsetinib dosing may require interruption or reduction because of adverse reactions, drug interactions, or organ impairment. A 100 mg capsule may not provide ideal flexibility for all dose levels.

A 25 mg or 50 mg capsule could support:

• Dose titration
• Step-down dosing
• Pediatric investigation
• More precise management of toxicity
• Combination regimens under clinical development

A lower-strength product would require bioequivalence or bridging work and could encounter separate regulatory and patent considerations. It also creates packaging and inventory complexity.

Pediatric formulation

A pediatric formulation is a longer-term opportunity rather than an immediate generic strategy. Potential presentations include:

• Mini-tablets
• Multiparticulate capsules
• Oral granules
• Powder for reconstitution
• Flavored oral suspension

An oral liquid would require careful control of solubility, precipitation, palatability, preservative compatibility, and dosing-device accuracy. Kinase inhibitors can have narrow tolerability margins, making dose uniformity particularly important.

Stability and packaging optimization

A formulation that is less sensitive to moisture, oxygen, or temperature could lower the cost of distribution. Excipient and packaging development should be considered together.

Relevant approaches include:

• Low-moisture capsule shells
• High-barrier blister packaging
• Desiccant-equipped bottles
• Oxygen scavengers where oxidation is relevant
• Reduced hygroscopicity through excipient selection
• Improved API particle engineering
• Longer in-use stability after bottle opening

The commercial value is highest in markets with long distribution routes, high humidity, or inconsistent cold-chain infrastructure. Gavreto is an oral solid, so cold-chain avoidance is already an advantage; the opportunity is to strengthen room-temperature stability and reduce packaging costs.

What patent opportunities exist for pralsetinib excipients?

The strongest patent positions would usually attach to a defined technical result, not to a generic excipient list.

Formulation patent opportunities

Potential claim categories include:

Patent category	Potential claim focus	Commercial strength
Food-effect-resistant formulation	Excipient ratio and exposure profile with fed dosing	High if supported by clinical data
Amorphous dispersion	Pralsetinib with polymer, glass-transition range, and dissolution profile	High
Nanocrystal formulation	Particle-size distribution and stabilizer system	Moderate to high
Lipid formulation	Specific oil, surfactant, cosurfactant, and loading range	Moderate to high
Low-moisture capsule	Shell composition and stability performance	Moderate
Dose-flexible product	25 mg or 50 mg capsule with defined dissolution and content uniformity	Moderate
Pediatric formulation	Granule or liquid composition with palatability and stability data	High if clinically adopted
Manufacturing process	Granulation, spray drying, milling, or encapsulation process	Moderate

A formulation patent should define measurable parameters, such as dissolution at multiple pH values, fed-versus-fasted exposure ratios, impurity limits, particle-size distribution, or storage stability. A claim that merely recites pralsetinib plus a standard diluent and lubricant is more vulnerable to obviousness and enablement challenges.

Manufacturing and trade-secret barriers

Manufacturing know-how can be more defensible than a narrow excipient patent when it controls:

• API deagglomeration
• Blend uniformity
• Surfactant distribution
• Lubrication time
• Capsule-fill weight variation
• Low-shear handling
• Scale-up from laboratory to commercial equipment

Process parameters can remain confidential where they are difficult to detect from the finished capsule. This is particularly relevant to contract manufacturing opportunities.

What is the FDA regulatory status of Gavreto?

Gavreto received accelerated FDA approval in September 2020 for metastatic RET fusion-positive non-small cell lung cancer. The FDA later approved an indication for advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy and for radioactive iodine-refractory advanced or metastatic RET fusion-positive thyroid cancer.[1,2]

The U.S. withdrawal was voluntary and related to commercial and regulatory circumstances rather than a finding that pralsetinib was unsafe. The withdrawal materially changes the U.S. commercial pathway for excipient suppliers and generic manufacturers.

Regulatory implications for a reformulated product

A reformulated pralsetinib product could require:

• An ANDA if a legally referenceable U.S. listed drug remains available for the relevant pathway
• A 505(b)(2) application for a modified formulation or new dosage form
• A new drug application in a market where the original product is not an available reference
• Clinical pharmacology studies for food-effect, bioavailability, or dose proportionality
• Comparative dissolution and stability studies
• Potential clinical efficacy or safety bridging if the formulation changes exposure materially

The U.S. withdrawal makes regulatory pathway analysis more complex. The commercial opportunity may be stronger in jurisdictions where Gavreto remains authorized or where pralsetinib can be developed under a local generic or hybrid pathway.

What is the Orange Book and exclusivity status of Gavreto?

Gavreto originally received five-year new chemical entity exclusivity because pralsetinib was a new active ingredient. Accelerated approval did not eliminate ordinary patent protection or regulatory exclusivity.

The key U.S. commercial facts are:

Issue	Assessment
New chemical entity exclusivity	Applied from the 2020 approval
Accelerated approval	Yes
Paragraph IV opportunity	Historically available against listed patents, subject to Orange Book listings and withdrawal status
Current U.S. launch economics	Reduced by voluntary withdrawal
Formulation-patent opportunity	More relevant to a differentiated 505(b)(2) product than to simple capsule copying
Biosimilar exposure	None, because pralsetinib is a small molecule
Generic exposure	Relevant in jurisdictions with an active reference product or legally usable reference

Pralsetinib is a small molecule, not a biologic. Biosimilar rules do not apply. Competitive risk arises from small-molecule generics, regional branded copies, and other RET inhibitors.

Which companies compete with or challenge pralsetinib?

The principal direct competitor is Retevmo, containing selpercatinib, marketed by Eli Lilly. Selpercatinib has overlapping RET fusion-positive lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer indications.

Product	Active ingredient	Company	Formulation profile	Competitive relevance
Gavreto	Pralsetinib	Blueprint/Roche	Immediate-release capsule	U.S. withdrawal reduces current U.S. presence
Retevmo	Selpercatinib	Eli Lilly	Oral capsule and additional dosage forms depending on market	Main direct branded comparator
Generic pralsetinib	Pralsetinib	Potential regional manufacturers	Likely capsule or tablet	Depends on local patent and regulatory status

Retevmo's broader dosage-form and lifecycle-development activity can make it more commercially attractive for excipient suppliers than Gavreto. Pralsetinib retains value where physicians prefer its clinical profile, where local authorization remains active, or where a manufacturer can secure a differentiated formulation.

How does Gavreto compare with Retevmo for excipient opportunities?

The main comparison is formulation flexibility.

Factor	Gavreto/pralsetinib	Retevmo/selpercatinib
Core formulation opportunity	Food-effect mitigation and capsule robustness	Dose flexibility, pediatric use, and administration convenience
U.S. commercial status	Weakened after withdrawal	Active branded commercial platform
Generic strategy	More dependent on regional markets	More relevant to future U.S. generic planning
Excipient differentiation	Strong opportunity if empty-stomach restriction is reduced	Strong opportunity where dosage-form expansion is pursued
Biosimilar risk	None	None
Direct competitive issue	Loss of U.S. commercial momentum	Greater current commercial continuity

A company seeking near-term excipient revenue may favor selpercatinib because the U.S. product is commercially active. A company seeking a lower-cost reformulation or regional licensing opportunity may still consider pralsetinib, particularly where regulatory rights and market access are available.

What licensing and commercial opportunities exist for Gavreto excipients?

The strongest licensing structures would involve a complete formulation platform rather than a single excipient.

High-value commercial targets

1. A fed-state-compatible pralsetinib formulation with human pharmacokinetic support.
2. A lower-strength capsule platform for dose reduction.
3. A pediatric granule or oral suspension system.
4. A high-humidity-stability capsule and blister package.
5. A manufacturing process that reduces content-uniformity failures.
6. A regional license for countries where pralsetinib remains commercially available.
7. A 505(b)(2) formulation with a differentiated administration claim.
8. A co-development agreement with a specialty pharmaceutical company focused on oncology generics.

The commercial model could include upfront licensing, milestone payments tied to bioequivalence or approval, supply of a proprietary excipient premix, and royalties on regional sales. A proprietary excipient blend is more defensible if it is supported by a patent family and a reproducible performance advantage.

What generic launch scenarios exist for pralsetinib?

Scenario 1: Conventional capsule

A manufacturer copies the immediate-release capsule using standard excipients and pursues a local generic pathway. This is the lowest-cost strategy but has limited differentiation and may face weak demand after the U.S. withdrawal.

Scenario 2: Improved capsule

A manufacturer develops a capsule with improved dissolution, lower moisture sensitivity, or better content uniformity. The product may compete in emerging markets where manufacturing reliability and storage conditions are important.

Scenario 3: Food-effect-mitigating product

A reformulated product supports less restrictive dosing. This has the highest commercial upside but requires the greatest clinical and regulatory investment.

Scenario 4: Pediatric or dose-flexible product

A 25 mg or 50 mg capsule, mini-tablet, or granule formulation can address treatment modification and pediatric development. This strategy may support orphan-drug or specialty-market positioning in selected jurisdictions.

How strong is the pralsetinib excipient patent opportunity?

The patent opportunity is moderate for routine excipient substitution and potentially strong for clinically demonstrated performance.

The most defensible claims would connect composition to a technical or clinical result:

• Reduced fed/fasted exposure difference
• Improved dissolution across physiological pH
• Reduced precipitation
• Improved chemical stability
• Better capsule-shell integrity
• More accurate low-dose administration
• Improved pediatric acceptability
• Reduced impurity formation during storage

A simple copy of the disclosed capsule excipients is unlikely to create a strong standalone commercial moat. A food-effect-resistant formulation, clinically validated pediatric product, or manufacturing process with measurable performance provides a stronger basis for patenting, licensing, and regulatory differentiation.

Key Takeaways

• Gavreto contains pralsetinib in an immediate-release 100 mg hard capsule.
• Its principal formulation weakness is the empty-stomach dosing requirement.
• Excipient opportunities center on wetting, dissolution, precipitation control, moisture stability, and dose flexibility.
• A conventional generic capsule has limited differentiation, particularly after the U.S. withdrawal.
• The strongest opportunity is a clinically supported formulation that reduces food-related exposure variability.
• Pralsetinib is a small molecule, so biosimilar competition is not relevant.
• Retevmo, containing selpercatinib, is the main branded comparator and currently offers a stronger active U.S. commercial platform.
• Patent strength will depend on measurable performance, not merely on listing alternative excipients.
• Regional licensing and contract-manufacturing opportunities may be more attractive than a direct U.S. generic strategy.

FAQs

Can pralsetinib be formulated as a tablet instead of a capsule?

Yes. A tablet could improve manufacturing efficiency, dose flexibility, and packaging, but it would require comparative dissolution, stability, bioavailability, and regulatory bridging work.

Is a food-independent Gavreto formulation commercially valuable?

Yes. Reducing or eliminating the empty-stomach restriction would address a direct prescribing and adherence limitation and could support a differentiated formulation patent.

Does pralsetinib have biosimilar competition?

No. Pralsetinib is a chemically synthesized small molecule. Potential competition comes from generic or hybrid small-molecule products.

Which excipient is most important for pralsetinib dissolution?

A surfactant such as sodium lauryl sulfate can materially affect wetting and dissolution, but the optimal system depends on the API particle properties, capsule fill, processing conditions, and precipitation behavior.

Is pediatric pralsetinib a realistic lifecycle opportunity?

Yes, but it would require a suitable dosage form, dose flexibility, palatability work, stability data, and clinical or regulatory support. Granules, mini-tablets, and oral liquids are the leading development concepts.

References

1. U.S. Food and Drug Administration. (2024). Gavreto (pralsetinib) prescribing information.
2. U.S. Food and Drug Administration. (2020). FDA approves pralsetinib for metastatic RET fusion-positive non-small cell lung cancer.
3. U.S. Food and Drug Administration. (2024). Withdrawal of approval of new drug application for Gavreto.
4. Blueprint Medicines Corporation. (2020). Gavreto (pralsetinib) U.S. approval announcement.
5. Eli Lilly and Company. (2024). Retevmo (selpercatinib) prescribing information.